RET-Mutant Medullary Thyroid Cancer: Selpercatinib Access Against Disease Pace
A newly superior, more selective drug exists for exactly her mutation — the argument is not whether it's better, but whether the days or weeks it might take to reach her are days her disease's own pace can afford to spend.
Sandra V. teaches third grade and was in the middle of planning a class field trip when she felt a firm lump in her own neck while adjusting a scarf — a finding her doctor initially thought was a benign nodule until a fine-needle biopsy came back suspicious for medullary thyroid cancer, confirmed on surgical pathology after thyroidectomy. Workup found nodal disease in the neck and mediastinum along with several liver lesions; genetic testing confirmed a somatic RET M918T mutation with no evidence of a germline mutation on confirmatory testing, ruling out a hereditary MEN2 syndrome. She is otherwise entirely healthy — no hypertension, no cardiac history, normal kidney function — which matters because it means the decision in front of the team is a genuine first-line choice, not one narrowed by comorbidity the way some of these decisions are.
What is narrowing the decision instead is her tumor's own pace. Her calcitonin and carcinoembryonic antigen levels, both elevated at diagnosis, have already roughly doubled over the six weeks since her first labs — a doubling time the team reads as genuinely aggressive, not indolent, disease. LIBRETTO-531, the randomized trial comparing selpercatinib against physician's choice of cabozantinib or vandetanib as first-line therapy, found selpercatinib reduced the risk of treatment failure or death by roughly three-quarters, a result strong enough to establish it as the preferred first-line option going forward. But selpercatinib is newer and less universally stocked than the multikinase inhibitors it outperformed, and for a patient whose own tumor markers are moving this quickly, the question the team keeps circling is whether the days or weeks a prior authorization might take are days her disease's own trajectory can actually afford to spend waiting.
It matters, too, that the germline testing came back negative. A hereditary RET mutation would have reframed this entirely — screening for pheochromocytoma before any systemic therapy, genetic counseling for her two children, a different urgency around surgical history. That her mutation is sporadic narrows today's conversation back to the one question actually in front of the team: which drug reaches a fast-moving, RET-driven tumor first, not how her family should be evaluated.
First-line systemic therapy planning
LIBRETTO-531 is randomized evidence, not just single-arm response data — selpercatinib reduced the risk of treatment failure or death by roughly three-quarters compared with physician's choice of cabozantinib or vandetanib. It's also far more selective for RET specifically, which means she avoids vandetanib's routine QT monitoring burden and cabozantinib's gastrointestinal perforation risk. I'd start selpercatinib as first-line, full stop.
I don't disagree with the efficacy or toxicity comparison — I'd raise a different, practical concern. Prior authorization for a newer targeted agent can genuinely take days to weeks depending on her insurer, and her calcitonin and CEA have roughly doubled in six weeks already. If access to selpercatinib is delayed, I'd rather start vandetanib or cabozantinib now than let genuinely aggressive disease keep moving while we wait for approval to come through.
I take the access concern seriously, but I'd push back on defaulting to a bridge therapy before we've actually tried the faster route. Most centers, including ours, can now get selpercatinib approved within days through expedited or manufacturer-assistance pathways given its established status — and her aggressive kinetics actually argue for getting her onto the most effective drug as fast as possible, not starting a second drug we'd likely need to switch her off of again shortly after, with its own washout and monitoring changes.
I'm not dismissing the possibility that access could be slower than we'd like — I'm suggesting we escalate for expedited approval today, with a concrete deadline in mind, before committing her to a bridge drug whose own startup isn't instantaneous either.
Agreed: pursue expedited authorization for selpercatinib immediately, with calcitonin and CEA rechecked in two weeks to confirm the doubling trend, rather than start a bridge therapy today.
Not agreed: how long a delay would be acceptable before switching to the bridge plan. The access-focused pharmacologist wanted a firm one-week deadline stated today, after which vandetanib would start regardless of authorization status; the second endocrine oncologist felt naming a rigid deadline before seeing how the authorization actually proceeds was premature. The team left the threshold unset, to be revisited concretely at the one-week mark rather than decided in the abstract now.